Rilecitinib

Clinical Indication

Comments

50 mg once daily, consider discontinuation of treatment if no response after 36 weeks. A patient card should be provided. NICE TA 958

The manufacturer of Litfulo® has provided a Prescriber Guide, which includes a prescriber checklist.

Date of classification

July 2024

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.